MELLODDY consortium

MELLODDY aims to leverage the world’s largest collection of small molecules with known biochemical or cellular activity to enable more accurate predictive models and increase efficiencies in drug discovery. This project aims to enhance predictive Machine Learning models on decentralised data of 10 pharmaceutical companies, without exposing proprietary information. EFPIA companies: Amgen Research (Munich) GMBH, Munchen, Germany Astellas Pharma Europe BV, Leiden, Netherlands Astrazeneca AB, Södertälje, Sweden Bayer Aktiengesellschaft, Leverkusen, Germany Boehringer Ingelheim International GmbH, Ingelheim, Germany Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom Institut De Recherches Servier, Suresnes, France Janssen Pharmaceutica Nv, Beerse, Belgium Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany Novartis Pharma AG, Basel, Switzerland Technology experts and universities: Budapesti Muszaki Es Gazdasagtudomanyi Egyetem, Budapest, Hungary Iktos, Paris, France Katholieke Universiteit Leuven, Leuven, Belgium Loodse GMBH, Hamburg, Germany Nvidia Switzerland AG, Zurich, Switzerland Owkin France, Paris, France Substra Foundation, Nantes, France